Themis Medicare Ltd

Contact details update

• Company Secretary/Compliance Officer email updated: sangameshwar.iyer@themismedicare.com to suresh.savaliya@themismedicare.com.
• RTA email updated: investor.helpdesk@in.mpms.mufg.com.

Financials (Q1 FY27)

• Net revenue ₹86.96 Cr; YoY decline 10.9%.
• EBITDA −₹52.42 Cr; EBITDA margin −60.28%.
• PBT ₹38.60 Cr; PAT ₹24.61 Cr; PAT margin 28.30%.
• Q1 FY26 revenue ₹97.58 Cr; EBITDA loss.
• Basic EPS ₹2.67.

Annual snapshot (FY26)

• Net revenue ₹342.24 Cr; YoY decline 15.6%.
• EBITDA ₹0.39 Cr; EBITDA margin 0.11%.
• PAT ₹1.14 Cr; PAT margin 0.33%.
• Total debt-to-equity 0.25; Market cap ₹1,084 Cr.

Balance sheet & liquidity

• Total assets ₹597.91 Cr; total equity ₹398.58 Cr.
• Cash ₹4.54 Cr; short-term borrowings ₹78.23 Cr.
• Current liabilities ₹166.16 Cr; long-term borrowings ₹21.86 Cr.
• Market cap ₹1,084 Cr as on 30 Jun 2026.

Strategic focus & growth

• Strategy: focus on Hospital business; in-house API development.
• R&D investment ~8% of revenue; long-term pipeline.
• Markets: RoW expansion CIS/Latin America/GCC; Phase II EU/USA.
• Manufacturing: 3 sites in Haridwar, Hyderabad, Vapi.

Risks & management

• Headwinds in API business; top-line contraction.
• One-off gains boosted Q1 PAT; sustainability uncertain.

Leadership & commentary

• MD & CEO Dr. Sachin Patel commented on profitability and cash flow focus.

Financial results

• Approved unaudited standalone and consolidated results for quarter ended 30 June 2026.
• Limited Review Reports of M/s Krishaan & Co attached.

CS/KMP changes

• Nagraj Mogaveera resigns as Interim CS, Compliance Officer, effective 13 Aug 2026.
• Suresh Savaliya appointed CS, Compliance Officer, and KMP, effective 13 Aug 2026.
• Savaliya brings 23 years' CS experience; previously with Reliance Industries and Essel Group.

Promoter share encumbrance

• Creation of pledge on 30/07/2026: 3.00 million shares (3.26%) encumbered by Vividhmargi Investments for borrowing from CTL Trusteeship.

Encumbrance release on promoter shares

• Event: Release of promoter pledge on Themis Medicare Limited shares.
• Promoter: Vividhmargi Investments Private Limited.
• Encumbrance type: Pledge.
• Before release: 1,500,000 shares pledged (1.63% of total share capital).
• Post-release: encumbrance released; promoter holding remains 26.52%.
• Entity in whose favor encumbrance held: Bajaj Finance Limited.
• Date of release: 08 July 2026.
• Total promoter stake pre-release: 2,44,29,460 shares (26.52%).
• Reason for encumbrance: Not Applicable.

Dematerialisation processing status

• Securities received for dematerialisation in the quarter were processed (accepted/rejected) and confirmed to the depositories.
• The corresponding securities have been listed on the stock exchanges where the issuer's securities are listed.
• Physical certificates for dematerialisation were mutilated and cancelled after verification; depository name substituted as registered owner within timelines.

Encumbrance creation on promoter shares

• Target: Themis Medicare Limited; promoter Vividhmargi Trust pledges 2,53,17,620 shares.
• Type: Pledge of equity shares under Debenture Trust Deed.
• Post-encumbrance promoter holding: 2,53,17,620 shares (40.96% of promoter holding).
• Pre-encumbrance: promoter encumbrances were 0.
• Encumbered shares represent 40.96% of total promoter holding (61,803,990 shares).
• Value of encumbered shares on date: Rs 28.42 crore.
• Debt secured: Rs 13.50 crore; funds for personal promoter use.
• Creditor/beneficiary: CTL Trusteeship Limited as Debenture Trustee.
• Debentures issued by OSS Software Solutions Labs; instrument not listed.
• Date of creation: 29 June 2026; trustees named: Dinesh Shantilal Patel, Jayshree Patel, Sachin Patel.

Encumbrance over Themis Medicare shares

• Nature: Encumbrance through pledge of 2,53,17,620 Themis Medicare shares.
• Acquirer: CTL Trusteeship Limited (debenture trustee); Transferor: Vividhmargi Trust.
• Shares: 2,53,17,620 shares, 27.49% of issued and diluted voting capital.
• Consideration: Nil; encumbrance rather than acquisition.
• Pre- and post- encumbrance holdings: 27.49% for acquirer and transferor.
• Change in control/promoter group: No change.
• Public shareholding unaffected.
• Regulatory basis: Regulation 29(1) of SEBI SAST Regulations, 2011.